Cytomegalovirus Anterior Uveitis: Clinical Manifestations, Diagnosis, Treatment, and Immunological Mechanisms

Viruses. 2023 Jan 9;15(1):185. doi: 10.3390/v15010185.

Abstract

Little is known regarding anterior uveitis (AU), the most common ocular disease associated with cytomegalovirus (CMV) infection in immunocompetent populations. CMV AU is highly prevalent in Asia, with a higher incidence in men. Clinically, it manifests mainly as anterior chamber inflammation and elevated intraocular pressure (IOP). Acute CMV AU may resemble Posner-Schlossman syndrome with its recurrent hypertensive iritis, while chronic CMV AU may resemble Fuchs uveitis because of its elevated IOP. Without prompt treatment, it may progress to glaucoma; therefore, early diagnosis is critical to prognosis. Knowledge regarding clinical features and aqueous humor analyses can facilitate accurate diagnoses; so, we compared and summarized these aspects. Early antiviral treatment reduces the risk of a glaucoma surgery requirement, and therapeutic effects vary based on drug delivery. Both oral valganciclovir and topical ganciclovir can produce positive clinical outcomes, and higher concentration and frequency are beneficial in chronic CMV retinitis. An extended antiviral course could prevent relapses, but should be limited to 6 months to prevent drug resistance and side effects. In this review, we have systematically summarized the pathogenesis, clinical features, diagnostic and therapeutic aspects, and immunological mechanisms of CMV AU with the goal of providing a theoretical foundation for early clinical diagnosis and treatment.

Keywords: anterior uveitis; cytomegalovirus; differential diagnosis; ganciclovir; immunocompetent; treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Cytomegalovirus / genetics
  • Cytomegalovirus Infections* / diagnosis
  • Cytomegalovirus Infections* / drug therapy
  • DNA, Viral / analysis
  • Eye Infections, Viral* / diagnosis
  • Eye Infections, Viral* / drug therapy
  • Ganciclovir
  • Glaucoma* / complications
  • Glaucoma* / drug therapy
  • Humans
  • Male
  • Retrospective Studies
  • Uveitis, Anterior* / complications
  • Uveitis, Anterior* / diagnosis
  • Uveitis, Anterior* / drug therapy

Substances

  • Ganciclovir
  • Antiviral Agents
  • DNA, Viral

Grants and funding

This work was supported by JSPS KAKENHI (grant no. JP 20K09824), a Grant on Rare and Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan (grant no. 22FC0201), a Research Program on Emerging and Re-emerging Infectious Diseases grant from the Japan Agency for Medical Research and Development, AMED (grant no. JP21fk0108124j), and MEXT, the establishment of university fellowships towards the creation of science technology innovation (grant no. JPMJFS2109).